ClinicalTrials.gg
Not yet recruitingNCT07860814Updated Oct 6, 2026

Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy

An observational study in Metabolic Dysfunction-steatohepatitis (MASH), sponsored by Radnet Management, Inc.. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionFatty LiverRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fatty Liver
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Fatty Liver.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Radnet Management, Inc. · Observational

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
524
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
6th of 48
524 · median 85
Started
2026
with 14 others
Observational
48 of 212
10 open now
Primary completion
2028-10
later than 32 of 47 live
Registered
210th of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 6th largest by planned enrollment of the 48 observational ones that give a count, is one of 15 that started in 2026, is one of 48 observational ones, reaches primary completion later than 32 of the 47 other live ones, and was the 210th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, non-interventional, observational study to evaluate the accuracy of 2 US (ultrasound) biomarkers that quantify liver tissue fat and stiffness: UDFF (ultrasound-derived fat fraction) and pSWE (point shear wave elastography) for determining MRI-defined eligibility for resmetirom (REZDIFFRA®) treatment and for monitoring treatment response using MRI-PDFF (proton density fat fraction) and MRE (magnetic resonance elastography) as reference standards.

Study Centers Planned:

3 clinical practice facilities in Houston TX .

Study Rationale:

MASLD (metabolic dysfunction-associated steatotic liver disease ) is a growing global epidemic and the most common liver disease worldwide. Approximately 25% of adults in the United States alone have hepatic steatosis in the absence of significant alcohol consumption and 1 in 4 of these adults are presumed to have MASH.

MASH has a higher likelihood of progression to irreversible liver damage including cirrhosis and hepatocellular carcinoma.

Despite advancements in the field, there is still a high unmet need for technologies to accurately and reliably grade liver steatosis and stage liver fibrosis for applications related to patient identification and monitoring response to therapeutic intervention.

The association between hepatic steatosis and fibrosis progression underscores the need to have accurate and reliable noninvasive tools to aid in the assessment and monitoring of both liver steatosis and fibrosis.

The combination of 2 US (ultrasound) biomarkers that quantify liver tissue fat and stiffness (UDFF and pSWE) may aid clinicians in streamlining patient care pathways and potentially avoid unwanted and invasive medical intervention.

Read the detailed description

This study will consist of 3 phases:

  1. Technologist Training: Pre-study training will be conducted for all US (ultrasound) and MRI technologists to ensure standardized image acquisition across study sites.
  2. A Pilot Study will be conducted in healthy adult participants to qualify imaging centers to participate in the Main Study.
  3. The Main Study will be conducted in adult participants suspected of MASH (metabolic dysfunction-steatohepatitis) (with moderate to advanced fibrosis consistent with F2-F3 to evaluate the diagnostic performance of the combination of 2 US (ultrasound) biomarkers (UDFF and pSWE) for determining MRI-defined eligibility for resmetirom treatment and for monitoring treatment response over time .

A Pilot Study will be conducted before the Main Study to verify image acquisition quality and data completeness, and to assess repeatability (US) and reproducibility (US and MRI). The Pilot Study will include 24 adult participants (n=8 participants/site across 3 imaging centers).

Each participant in the pilot study will undergo 4 US (ultrasound) scans (2 scans each by 2 Certified US Technologists).

All US scans will be performed on SIEMENS ACUSON Sequoia systems using the 5C1 transducer and the same software version throughout the study. Repeated US scans will be separated by ≥5 minutes, with participants repositioned between scans by the Certified US Technologists.

Each participant in the pilot study will also undergo 2 MRI scans (1 scan each by 2 Certified MRI Technologists):

MR scans will be performed using either the SIEMENS MAGNETOM Skyra 3T or GE SIGNA PIONEER 3T, depending on scheduling and site availability. The MR scanner will be running the same software version throughout the study.

Data from participants in the Pilot Study will not be included in the analysis of the Main Study.

Data Quality Verification :

All pilot data will be reviewed by Siemens to verify image acquisition quality, completeness, and adherence to the imaging protocol.

Repeatability and reproducibility will be evaluated in the Pilot Study.

Main Study

Participants will be recruited from clinical practices in the Houston, Texas area by hepatologists, gastroenterologists, and other referring clinicians. US (ultrasound) and MRI examinations will be performed across 3 Sponsor imaging centers in the Houston area. All participants will undergo Baseline US (ultrasound) biomarkers (UDFF, pSWE) and MRI biomarkers (MRI-PDFF, MRE) on the same day.

Blinding

  • Referring physicians will be blinded to US (ultrasound) (UDFF and pSWE) results, and thus decisions to prescribe resmetirom will be made based solely on MRI biomarkers (ie, MRI-PDFF and MRE) and clinical assessment.
  • US (ultrasound) operators will be blinded to results from MRI biomarkers (MRI-PDFF and MRE).
  • MRI operators will be blinded to results from US (ultrasound) biomarkers (UDFF and pSWE).

Duration of Study Participation

  • Pilot Study: 1 day, in addition to the Screening Visit
  • Main Study :
  • Participants NOT treated with resmetirom: Screening(consenting)and day 1 baseline MRI and US(2 visits total);
  • Participants treated with resmetirom (prescribed by their referring physician based on Baseline MRI results and clinical assessment): Screening (consenting), day 1 baseline MRI and US then at months 6, 12 and 24 (5 visits total).

Study Assessments

  • Record demographics
  • Record medication history since last visit
  • Record laboratory test results since last visit
  • Perform US (ultrasound)
  • Perform MRI
  • Record/report SAEs
03

Conditions studied

  • Metabolic Dysfunction-steatohepatitis (MASH)

Browse trials for

Keywords

  • MASH
  • MASLD
  • UDFF
  • pSWE
  • MRI-PDFF
  • MRE
  • Madrigal
  • Siemens
  • RadNet
  • Elastography
  • Resmetirom
  • Rezdiffra
  • MRI
  • ultrasound
  • biomarkers
  • fatty
  • liver
  • fibrosis
  • steatosis
  • stiffness
  • metabolic
  • dysfunction
04

In context

Fatty Liver Reclassified

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

This study's planned enrollment of 524 is above the median of 150 across 207 observational studies indexed under Fatty Liver.

Browse Fatty Liver studies →

Lead sponsor

This is the only study on the registry with Radnet Management, Inc. as lead sponsor.

Compared within Fatty Liver, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants must be fully informed of the potential benefits of approved products and make an informed decision that they prefer to participate in a clinical study. Regulatory, ethical, and study oversight considerations are provided in the protocol.

Participants will be recruited from clinical practices in the Houston, Texas area by hepatologists, gastroenterologists, and other referring clinicians.

  • Participants in the Pilot Study will be healthy adult males or females, age ≥18 years.
  • Participants in the Main Study will be adult males or females, age ≥18 years, suspected of MASH with moderate to advanced fibrosis consistent with F2-F3.

Participants will be eligible if they meet ALL inclusion criteria and NONE of the exclusion criteria at Screening.

Eligibility criteria

Enrollment Criteria

Participants will be recruited from clinical practices in the Houston, Texas area by hepatologists, gastroenterologists, and other referring clinicians.

Inclusion Criteria (Pilot Study):

  • Participants must meet the following criteria:
  • Healthy adults (≥18 years) with no known liver diseases

Inclusion Criteria (Main Study):

  • Participants must meet the following criteria:
  • Adults (≥18 years) suspected of MASH with moderate to advanced fibrosis consistent with F2-F3 with no other known liver disease

Exclusion Criteria (Pilot Study, Main Study):

Participants meeting ANY of the following criteria will be excluded:

  • Use of steatogenic or hepatotoxic medications (eg, such as prednisone, amiodarone, methotrexate, tamoxifen)
  • to MRI
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
524 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Diagnostic performance of UDFF (ultrasound-derived fat fraction)

    Ultrasound criteria associated with elevated liver fat at baseline: UDFF ≥8%

    Time frame: Enrollment Day 1 Baseline

  2. Diagnostic performance of Ultrasound pSWE (point shear wave elastography)

    Ultrasound criteria consistent with MASH F2-F3 fibrosis at baseline: pSWE ≥7 and \<17 kPa

    Time frame: Enrollment Day 1 Baseline

Secondary outcomes

  1. The accuracy of the Ultrasound biomarker pSWE (point shear wave elastography) for monitoring resmetirom treatment response over time.

    Percent changes in Ultrasound pSWE from baseline to follow-up period are tested for statistical equivalence.

    Time frame: 6 months to 24 months of follow-up period

  2. The accuracy of the Ultrasound biomarker UDFF (ultrasound-derived fat fraction) for monitoring resmetirom treatment response over time.

    Percent changes in UDFF from baseline to follow-up period are tested for statistical equivalence

    Time frame: 6 months to 24 months of follow-up period

  3. Corresponding percent changes in MRI-PDFF (proton density fat fraction) from baseline to follow- up period are tested for statistical equivalence

    MR criteria associated with elevated liver fat at baseline: PDFF ≥8%

    Time frame: 6 months to 24 months follow-up period

  4. Corresponding percent changes in MRE (magnetic resonance elastography) from baseline to followup period are tested for statistical equivalence

    MR criteria consistent with MASH F2-F3 fibrosis at baseline: MRE ≥3.3 and \<5 kPa

    Time frame: 6 months to 24 months follow-up period

  5. Correlation between percent changes in imaging biomarkers for monitoring resmetirom treatment response over time.

    Percent changes in UDFF and MRI-PDFF values from baseline to follow-up period and Percent changes in pSWE and MRE values from baseline to follow-up period.

    Time frame: 6 months to 24 months follow-up period

Other outcomes

  1. To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.

    • Assessment of the influence of GLP-1 therapy use using a subgroup analysis.

    Time frame: Enrollment Day 1 Baseline to 24 months follow-up period

  2. To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.

    • Assessment of the influence of weight change using a subgroup analysis.

    Time frame: Enrollment Day 1 Baseline to 24 months followup period

  3. To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.

    • Assessment of the association of BMI

    Time frame: Enrollment Day 1 Baseline to 24 months follow-up period

  4. To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.

    • Assessment of the association of MR-R2 (speed of signal delay)

    Time frame: Enrollment Day 1 Baseline to 24 months follow-up period.

  5. To evaluate factors influencing imaging biomarkers MRI-PDFF, MRE, UDFF and pSWE.

    Assessment of association of laboratory findings

    Time frame: Enrollment Day 1 Baseline to 24 months follow-up period

08

Study locations

3 sites
  • HMI/Campbell
    Houston, Texas 77055, United States
  • HMI/Energy Corridor
    Houston, Texas 77079, United States
  • HMI/Pearland
    Pearland, Texas 77581, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 88 non-industry observational studies under Fatty Liver, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 68. This study's planned 24 months is below that.

Counting every sponsor, half of 97 studies reached it within 33 months; a quarter within 20 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Oct 6, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07860814
Lead sponsor
Radnet Management, Inc.
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Senior Vice President of Research
Contact
Kristi.Maya@radnet.com
+1 562-981-6101
Clinical Research Regulatory Specialist
Contact
Jacqueline.Bral@radnet.com
+1 562-206-7701
Randall Stenoien, MD
principal investigator · RadNet Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion